MilliporeSigma
  • Home
  • Search Results
  • Lowering of elevated tissue PCO2 in a hemorrhagic shock rat model after reinfusion of a novel nanobiotechnological polyhemoglobin-superoxide dismutase-catalase-carbonic anhydrase that is an oxygen and a carbon dioxide carrier with enhanced antioxidant properties.

Lowering of elevated tissue PCO2 in a hemorrhagic shock rat model after reinfusion of a novel nanobiotechnological polyhemoglobin-superoxide dismutase-catalase-carbonic anhydrase that is an oxygen and a carbon dioxide carrier with enhanced antioxidant properties.

Artificial cells, nanomedicine, and biotechnology (2013-01-26)
Yuzhu Bian, Gao Wei, Thomas M S Chang
ABSTRACT

Even though erythrocytes transport both oxygen and carbon dioxide, research on blood substitutes has concentrated on the transport of oxygen and its vasoactivity and oxidative effects. Recent study in a hemorrhagic shock animal model shows that the degree of tissue PCO(2) elevation is directly related to mortality rates. We therefore prepared a novel nanobiotechnological carrier for both O(2) and CO(2) with enhanced antioxidant properties. This is based on the use of glutaraldehyde to crosslink stroma free hemoglobin (SFHb), superoxide dismutase (SOD), catalase (CAT) and carbonic anhydrase (CA) to form a soluble PolySFHb-SOD-CAT-CA. It was compared to blood and different resuscitation fluids on the ability to lower elevated tissue PCO(2) in a 2/3 blood volume loss rat hemorrhagic shock model. Sixty minutes of sustained hemorrhagic shock at 30 mm Hg resulted in the increase of tissue PCO(2) to 95 mm ± 3 mmHg from the control level of 55 mm Hg. Reinfusion of whole blood (Hb 15 g/dL with its RBC enzymes) lowered the tissue PCO2 to 72 ± 4.5 mmHg 60 minutes after reinfusion. PolySFHb-SOD-CAT-CA (SFHb 10 g/dL plus additional enzymes) was more effective than whole blood in lowering PCO(2) lowering this to 66.2 ± 3.5 mmHg. Ringer's Lactated solution or polyhemoglobin lowered the elevated PCO2 only slightly to 87 ± 4.5 mmHg and 84.8 ± 1.5 mmHg, respectively. Moreover, ST-elevation for whole blood (Hb 15 g/dL) and PolySFHb-SOD-CAT-CA (Hb 10 g/dL) was respectively 12.8% ± 4% and 13.0% ± 2% of the control 60 minutes after reinfusion. Both are significantly better than those in the Ringer's lactated group and the PolyHb group. In conclusion, this novel approach for blood substitute design has resulted in a novel nanobiotechnological carrier for both O(2) and CO(2) with enhanced antioxidant properties.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Carbonic Anhydrase from bovine erythrocytes, BioReagent, suitable for GFC marker
Sigma-Aldrich
Carbonic Anhydrase from bovine erythrocytes, For use as a marker in SDS-PAGE
Sigma-Aldrich
Carbonic Anhydrase from bovine erythrocytes, non-denaturing PAGE marker
Sigma-Aldrich
Carbonic Anhydrase from bovine erythrocytes, lyophilized powder, ≥2,000 W-A units/mg protein
Supelco
Carbonic Anhydrase I from human erythrocytes, Isoelectric focusing marker, pI 6.6
Sigma-Aldrich
Carbonic Anhydrase I from human erythrocytes
Sigma-Aldrich
Carbonic Anhydrase from bovine erythrocytes, ≥95% (SDS-PAGE), specific activity ≥3,500 W-A units/mg protein, lyophilized powder
Sigma-Aldrich
Carbonic Anhydrase Isozyme II from bovine erythrocytes, lyophilized powder, ≥3,000 W-A units/mg protein
Sigma-Aldrich
Carbonic Anhydrase Isozyme II human, ≥80%, powder, ≥3,000 W-A units/mg protein
Sigma-Aldrich
Carbonic Anhydrase Isozyme II from bovine erythrocytes, lyophilized powder, ≥2,000 W-A units/mg protein
Sigma-Aldrich
Carbonic Anhydrase Isozyme II from bovine erythrocytes, Isoelectric focusing marker, pI 5.4
Sigma-Aldrich
Carbonic Anhydrase II human, recombinant, expressed in E. coli, buffered aqueous solution
Sigma-Aldrich
Carbonic Anhydrase II bovine, ≥90% (SDS-PAGE), recombinant, expressed in E. coli, ≥5,000 units/mg protein, buffered aqueous solution